Our website uses cookies to enhance and personalize your experience and to display advertisements (if any). Our website may also include third party cookies such as Google Adsense, Google Analytics, Youtube. By using the website, you consent to the use of cookies. We have updated our Privacy Policy. Please click the button to view our Privacy Policy.

FTC Questions Prescription Managers Over High Insulin Costs

FTC Questions Prescription Managers Over High Insulin Costs

On September 20, 2024, the Federal Trade Commission (FTC) initiated a lawsuit against the three largest pharmacy benefit managers (PBMs) in the United States, alleging that their practices have led to inflated insulin prices. The implicated PBMs include CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth’s Optum Rx, which collectively serve 80% of the national prescription drug market.

Acting on behalf of employers and various government health programs, these PBMs are responsible for negotiating drug prices, managing payments to pharmacies, and determining the availability and pricing of drugs for consumers. The FTC complaint, which is currently confidential, accuses these PBMs of engaging in practices that not only distort competition but also negatively impact consumers by pushing more expensive insulin products that benefit the PBMs financially.

The FTC seeks to enforce measures that prevent these executives from promoting drugs that generate greater profits at the expense of consumer welfare and fair market practices. This action underscores the government’s growing scrutiny of healthcare middlemen whose actions impact drug costs and availability.

By Mia Murphy

You may be interested in